Public Company Healthcare

Elanco

Indianapolis, IN, United States

Global animal health company with products and knowledge services for livestock and companion animals, including vaccines, pharmaceuticals and nutrition products.

Focus Areas
Animal Health / Veterinary Pharmaceuticals, Companion Animal Therapeutics, Animal health vaccines
Website
elanco.com

Tracked deals

3

3 tracked deals across 2019-2026.

Recent pace

1

1 tracked deal announced in the last 12 months.

Deal mix

Buyout

3 buyout

Elanco Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Elanco. 2 2019 ~1 est. 1 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Elanco Acquires AHV International
    May 8, 2026
    Buyer
    Elanco
    Target
    AHV International
    Industry
    Healthcare Services
    Location
    Overijssel, Netherlands
    Type
    Buyout

    Elanco completed its acquisition of AHV International, a Dutch innovator in animal health. Elanco said the deal strengthens its position in the global dairy market by expanding its portfolio for transition cows and improving dairy production, including technologies such as StopLac and Quorum Sensing.

  • Elanco Acquires Prevtec Microbia
    August 1, 2019
    Buyer
    Elanco Animal Health Incorporated
    Target
    Prevtec Microbia Inc.
    Seller
    Prevtec Microbia shareholders
    Industry
    Biotechnology
    Location
    Quebec, Canada
    Type
    Buyout

    Elanco Animal Health acquired Montreal-based Prevtec Microbia, maker of the Coliprotec swine E. coli vaccine line, in an all-cash transaction of CAD $78.5 million (approx. $59.9M USD) plus contingent payments of up to CAD $21.5 million. The deal brings Prevtec's commercial vaccines and R&D pipeline into Elanco to expand its swine portfolio and provide non-antibiotic alternatives for swine producers globally.

  • Elanco Animal Health Acquires Aratana Therapeutics
    July 18, 2019
    Buyer
    Elanco Animal Health Incorporated
    Target
    Aratana Therapeutics
    Industry
    Pharmaceuticals
    Location
    Kansas, United States
    Type
    Buyout

    Elanco Animal Health Incorporated completed its acquisition of Aratana Therapeutics, a developer and commercializer of specialty therapeutics for dogs and cats, including Galliprant, Entyce and Nocita. The deal expands Elanco's companion animal product portfolio and establishes a dedicated specialty veterinary commercial team to integrate Aratana's field force and pipeline.

Related Acquisition Pages

Biotechnology Buyers & Acquisitions 1 tracked deal by Elanco. Healthcare Services Buyers & Acquisitions 1 tracked deal by Elanco. Pharmaceuticals Buyers & Acquisitions 1 tracked deal by Elanco. Acquisitions in Kansas 1 tracked deal by Elanco.

Related articles

Selling a company? Get in front of buyers like Elanco

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →